A Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.

Trial Profile

A Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2014

At a glance

  • Drugs Siltuximab (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Giant lymph node hyperplasia; Lymphoid leukaemia; Multiple myeloma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Centocor
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2011 Actual end date (April 2011) added as reported by ClinicalTrials.gov.
    • 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top